UBS Group
CNSP icon

UBS Group’s CNS Pharmaceuticals CNSP Stock Holding History

UBS Group’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.74K Buy
729
+118
+19% +$489 ﹤0.01% 9450
2025
Q4 		$3.21K Sell
611
-9,909
-94% -$74.3K ﹤0.01% 9077
2025
Q3 		$94.7K Buy
10,520
+7,845
+293% +$63.1K ﹤0.01% 7158
2025
Q2 		$26.5K Buy
2,675
+677
+34% +$8.47K ﹤0.01% 8253
2025
Q1 		$32.6K Buy
1,998
+1,891
+1,767% +$92.5K ﹤0.01% 7885
2024
Q4 		$7.73K Sell
107
-196
-65% -$13.9K ﹤0.01% 8457
2024
Q3 		$23.8K Buy
303
+299
+7,475% +$85.8K ﹤0.01% 7267
2024
Q2 		$4.15K Buy
+4
New +$21.3K ﹤0.01% 8126
2023
Q4 		– Hold
0
– -$63 – 9371
2023
Q3 		– Hold
0
– – – 8972
2023
Q2 		– Hold
0
– – – 7742
2023
Q1 		– Hold
0
– – – 8510
2022
Q4 		– Hold
0
– – – 9602
2022
Q1 		– Hold
0
– -$3K – 10323
2021
Q4 		– Hold
0
– – – 9650
2021
Q3 		– Hold
0
– -$9K – 9598
2021
Q2 		– Hold
0
– – – 8128
2021
Q1 		– Hold
0
– – – 8506
2020
Q4 		– Hold
0
– -$7K – 8422
2020
Q3 		– Hold
0
– – – 7102
2020
Q2 		– Hold
0
– -$4K – 7975
2020
Q1 		– Hold
0
– – – 7375

Other funds holding CNSP

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group's CNSP Position: Q1 2026 in Review

UBS Group increased its CNS Pharmaceuticals (CNSP) stake by 19% in Q1 2026, buying an estimated $489 and bringing the position to 729 shares worth $1.74K. The position accounts for ﹤0.01% of the portfolio, ranked #9450.

UBS Group first reported a position in CNSP in Q2 2024 and has held it in 8 quarters since. The position peaked at $94.7K in Q3 2025. 12 funds tracked by Wall St. Rank hold CNSP as of Q1 2026.

  • UBS Group held 729 shares of CNS Pharmaceuticals worth $1.74K as of Q1 2026.
  • UBS Group bought 118 CNS Pharmaceuticals shares in Q1 2026, an estimated $489.
  • CNS Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9450 holding.
  • UBS Group first reported a position in CNS Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • UBS Group's CNS Pharmaceuticals position peaked at $94.7K in Q3 2025.
  • 12 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.